Mu-opioid receptor–Cannabinoid receptor 1 heterodimer (MOR-CB1)

The Mu-opioid receptor–Cannabinoid receptor 1 (MOR-CB1) heterodimer is a functional protein complex formed by the physical association of two distinct G protein-coupled receptors: the mu-opioid receptor and the cannabinoid receptor 1 [2.2.1, 2.3.1]. These receptors are co-localized in key neural circuits involved in pain processing and reward, such as the spinal cord dorsal horn and the ventral tegmental area [3.1.2, 3.3.4]. Heterodimerization significantly alters the pharmacological properties of the individual receptors, often leading to reciprocal inhibition where the activation of one receptor attenuates the signaling and physiological responses of the other [2.3.1, 2.3.3]. This cross-talk is a critical modulator of opioid-induced analgesia, tolerance, and withdrawal, making the heteromer a significant target for drug development [2.2.1, 3.2.1]. Therapeutic strategies targeting the MOR-CB1 complex, such as the use of bivalent ligands or allosteric modulators, aim to provide potent pain relief while minimizing the adverse effects and addictive potential associated with traditional opioid therapies [3.1.1, 3.3.1]. Research indicates that specific bivalent ligands can bridge the protomers of the heteromer to produce antinociception without the development of tolerance [3.1.1, 3.2.3]. Furthermore, the interaction between these systems is implicated in the rewarding properties of drugs of abuse, suggesting potential applications in treating substance use disorders [2.3.2, 3.2.1]. Understanding the molecular dynamics of the MOR-CB1 complex provides a pathway for precision medicine in managing chronic pain and addiction [2.2.1, 3.3.1].

Other names

Mu-opioid receptor-Cannabinoid receptor 1 heteromerMOR-CB1R complexMOP-CB1 heteromerMu-opioid-Cannabinoid receptor heterodimer

The MOR-CB1 heterodimer functions through reciprocal allosteric modulation, where the activation of one receptor protomer (e.g., CB1) inhibits the G-protein signaling and physiological responses (such as neuritogenesis) of the other (e.g., MOR) [2.3.1, 2.3.3]. This interaction can also involve cross-antagonism and biased signaling through pathways like Src-STAT3 and ERK1/2 [2.2.1, 2.3.2].